VALNEVA
Research VALNEVA (AYJ) on Bullrun: market cap EUR 561.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAYJ
- ExchangeMU
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 561.35M
- Financial periodQ1 2026
- RevenueEUR 30.90M
- Net income-EUR 32.07M
- Free cash flow-EUR 565.00K
- Gross margin15.3%
Valuation Snapshot
latest market cap is EUR 561.35M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 174.66M | -EUR 115.19M | -EUR 57.31M | 38.7% | -0.68 | EUR 109.65M | EUR 179.17M | EUR 106.17M |
| FY2024 | EUR 169.58M | -EUR 12.25M | -EUR 81.08M | 41.9% | -0.08 | EUR 168.27M | EUR 187.37M | EUR 181.25M |
| FY2023 | EUR 153.71M | -EUR 101.43M | -EUR 216.98M | 34.4% | -0.73 | EUR 126.08M | EUR 176.85M | EUR 128.25M |
| FY2022 | EUR 361.30M | -EUR 143.28M | -EUR 274.59M | 10.2% | -1.24 | EUR 286.53M | EUR 98.81M | EUR 219.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 561.35M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About VALNEVA
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VALNEVA's market cap?
VALNEVA's market capitalization is EUR 561.35M.
What does VALNEVA do?
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.